Company news

INmune Bio Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

INmune Bio Announces FDA Removal of Clinical Hold for Alzheimer’s Disease Program

January 29, 2024

INmune Bio Announces First Patient Dosed in a Phase 1/2 Study of INKmune™ in Patients with Metastatic Castration-Resistant Prostate Cancer

January 1, 2024

INmune Bio Provides Update Regarding Global Alzheimer’s Phase II Clinical Trial and Clinical Hold Issued by the United States FDA

December 17, 2023

INmune Bio Inc. Demonstrates that INB03 Enhances the Uptake of Trastuzumab Deruxtecan in HER2+ Breast Cancer with MUC4 Expression in Poster Presented at San Antonio Breast Cancer Symposium

November 28, 2023

INmune Bio Receives EMA’s Authorization in France and Spain for Phase II Clinical Trial of XPro™ for Early Alzheimer’s Disease

November 26, 2023

INmune Bio Inc. Announces Expansion of Phase II Clinical Trial for Alzheimer’s Disease in Europe

November 14, 2023

INmune Bio Inc. Announces Third Quarter 2023 Results and Provides Business Update

October 31, 2023

INmune Bio Inc. Patent Claims Covering INB16 Cell Line and INKmune™ Therapeutic Composition given Favorable Patentability Opinion by International Search Authority

October 30, 2023

INmune Bio Inc. Presents Preclinical Data at SITC 2023 Showing INB03 is an Innate Immune Check Point Inhibitor that Downregulates SIRPα

October 29, 2023

INmune Bio Inc. Presents New Biomarker and Feasibility Data from Phase 1b Study Supporting the Use of XPro™ to Treat Alzheimer’s Disease at Clinical Trials on Alzheimer’s Disease (CTAD) Conference

October 16, 2023

INmune Bio Inc. to Report Third Quarter 2023 Financial Results and Provide a Corporate Update on Wednesday, November 1

October 15, 2023

INmune Bio Inc. to Present at Baird Global Healthcare Conference and H.C Wainwright 25th Annual Global Investment Conference

September 6, 2023

INmune Bio Inc. Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Phase 2 Clinical Trial in Alzheimer’s Disease

September 4, 2023

INmune Bio Inc. Announces Second Quarter 2023 Results and Provides Business Update

August 6, 2023

INmune Bio Inc. to Present at the BTIG Virtual Biotechnology Conference

July 31, 2023

INmune Bio, Inc. to Report Second Quarter 2023 Financial Results and Provide a Corporate Update on Monday, August 7

July 30, 2023

INmune Bio Inc. to Deliver Keynote Talk at 5th World Aging and Rejuvenation Conference.

July 11, 2023

INmune Bio Inc. Announces Novel MRI Biomarker Data Demonstrating Improvement in Gray Matter in Patients with Alzheimer’s Disease

July 10, 2023

INmune Bio Inc. Announces Data Presented at the 16th European Meeting on Glial Cells in Health and Disease Shows that XPro™ Promotes Remyelination by Affecting Astroglial and Microglial Biology

July 9, 2023

INmune Bio Inc.’s Chief Scientific Officer, Mark Lowdell, Ph.D. to Present Plenary Talk at International Society of Cell & Gene Therapy

May 23, 2023

INmune Bio, Inc. Announces FDA Clearance of IND Application for INKmune™, a Natural Killer Therapy, for a Phase I/II Trial in Metastatic Castration-Resistant Prostate Cancer

May 7, 2023

INmune Bio Inc. Announces First Quarter 2023 Results and Provides Business Update

May 2, 2023

INmune Bio, Inc. to Report First Quarter 2023 Financial Results and Provide a Corporate Update on Wednesday, May 3

April 23, 2023

XPro1595 Improves Outcomes in a Mouse Model of TBI-induced Alzheimer’s Disease

April 18, 2023

INmune Bio, Inc. to Present Preclinical Data at the 2023 AACR Annual Meeting Showing Improved Outcomes in High-Risk Breast Cancer by Targeting MUC4 Expression with INB03

April 10, 2023

INmune Bio, Inc. Announces Submission of Investigational New Drug (IND) Application for INKmune™ to the U.S. Food and Drug Administration for Treatment of Metastatic Castration-Resistant Prostate Cancer

April 2, 2023

INmune Bio, Inc. Announces 2022 Results and Provides Business Update

March 1, 2023

INmune Bio, Inc. to Report Fourth Quarter and Full-Year 2022 Results and Provide a Corporate Update on Thursday, March 2

February 20, 2023

INmune Bio, Inc. Receives Approximately $6.4 Million in Research and Development Rebates from Australia and the United Kingdom

February 7, 2023

INmune Bio, Inc. Announces Pre-Clinical Data That Support a Pioneering Approach to Treating Duchenne Muscular Dystrophy

January 24, 2023

INmune Bio, Inc. Reports Combination Therapy with INB03™ Overcomes Resistance to Trastuzumab-Deruxtecan in MUC4 expressing HER2+ Breast Cancer

December 5, 2022

INmune Bio, Inc. Receives Health Canada “No Objection Letter” to Commence Clinical Trial of XPro1595 in Mild Alzheimer’s Disease

November 13, 2022

INmune Bio, Inc. Announces Third Quarter 2022 Results and Provides Business Update

November 1, 2022

INmune Bio, Inc. to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on Wednesday, November 2

October 25, 2022

INmune Bio, Inc. Announces Positive Solid Tumor Efficacy Data in Multiple Cancer Cell Lines for INKmune

October 18, 2022

INmune Bio, Inc. Announces Second Quarter 2022 Results and Provides Business Update

August 2, 2022

INmune Bio, Inc. to Report Second Quarter 2022 Financial Results and Provide a Corporate Update on Wednesday, August 3

July 26, 2022

USPTO Issues Patent Covering Use of XPro™ for Treatment of CNS Diseases

June 21, 2022

INmune Bio, Inc. Presents Data on Combination Therapy with INB03™ on Overcoming Resistance to HER2 Targeted Therapies in Breast Cancer

June 15, 2022

INmune Bio, Inc. to Provide Additional Manufacturing Information to FDA as Part of IND Application for XPro1595™ in Alzheimer’s Disease

May 22, 2022

INmune Bio, Inc. Presents Data Demonstrating XPro™ Promotes Remyelination in Gray Matter at 3rd European Conference on Neuroinflammation

May 9, 2022

INmune Bio, Inc. Announces First Quarter 2022 Results and Provides Business Update

May 4, 2022

INmune Bio, Inc. to Report First Quarter 2022 Financial Results and Provide a Corporate Update on Thursday, May 5

April 27, 2022

INmune Bio Announces First Patient Dosed in Phase 2 XPro1595 Trial for Treatment of Neuroinflammation as a Cause of Alzheimer’s disease

April 12, 2022

INmune Bio, Inc. Announces Company’s CSO Dr. Mark Lowdell to Co-Host the “NK Cells in Solid Tumors” Workshop at Innate Killer Summit

March 29, 2022

INmune Bio, Inc. Announces Nine Data Presentations at AD/PD™ 2022 - International Conference on Alzheimer's and Parkinson's Diseases

March 14, 2022

INmune Bio, Inc. Announces Fourth Quarter and Full Year 2021 Results and Provides Business Update

March 2, 2022

INmune Bio, Inc. to Report Fourth Quarter 2021 Financial Results and Provide a Corporate Update on Thursday, March 3

February 22, 2022

INmune Bio, Inc. Announces Research Collaboration with Chinese University of Hong Kong to Evaluate INKmune in Nasopharyngeal Cancer

January 24, 2022

INmune Bio, Inc. Announces Key Breast Cancer Treatment Resistance Data to be Presented at the 2021 San Antonio Breast Cancer Symposium

December 8, 2021

← Newer news releases · Older news releases →

Calls

The 5 newest of 22 calls. Every call is listed under its year.

Decks

The 5 newest of 42 decks. Every deck is listed under its year.